181 related articles for article (PubMed ID: 23050965)
1. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum.
Ali AY; Farrand L; Kim JY; Byun S; Suh JY; Lee HJ; Tsang BK
Ann N Y Acad Sci; 2012 Oct; 1271(1):58-67. PubMed ID: 23050965
[TBL] [Abstract][Full Text] [Related]
2. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
3. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Bezler M; Hengstler JG; Ullrich A
Mol Oncol; 2012 Oct; 6(5):516-29. PubMed ID: 22841590
[TBL] [Abstract][Full Text] [Related]
5. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
6. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
[TBL] [Abstract][Full Text] [Related]
7. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
8. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
[TBL] [Abstract][Full Text] [Related]
9. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
10. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
[TBL] [Abstract][Full Text] [Related]
11. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
12. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
[TBL] [Abstract][Full Text] [Related]
13. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
14. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway.
Gao L; Chen M; Ouyang Y; Li R; Zhang X; Gao X; Lin S; Wang X
Life Sci; 2018 Jun; 202():188-194. PubMed ID: 29625193
[TBL] [Abstract][Full Text] [Related]
15. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
17. Akt activation by Ca
Gocher AM; Azabdaftari G; Euscher LM; Dai S; Karacosta LG; Franke TF; Edelman AM
J Biol Chem; 2017 Aug; 292(34):14188-14204. PubMed ID: 28634229
[TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance in human ovarian cancer cells.
Hu JL; Hu XL; Guo AY; Wang CJ; Wen YY; Cang SD
Oncotarget; 2017 Jul; 8(30):49380-49394. PubMed ID: 28537902
[TBL] [Abstract][Full Text] [Related]
19. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
